|
Jubilant Organosys Ltd, headquartered at Noida, near New
Delhi, announced today that its Bangalore
based subsidiary Jubilant Biosys Ltd, has entered into a drug discovery
partnership with BioLeap, LLC, USA. Under this partnership BioLeap and Jubilant
will integrate BioLeap’s leading edge computational fragment based drug design
platform with Jubilant’s expertise in chemistry, biology and crystallography to
offer a highly competitive preclinical drug development platform. The
partnership will provide customers with integrated pre-clinical drug discovery
services from lead identification and optimization to IND
(Investigational New Drug) candidate selection, for multiple therapeutic areas.
Commenting on the development, Sri Mosur, CEO &
President,Jubilant Biosys, said:
" We are very pleased to partner with BioLeap to offer the
pharmaceutical industry our combined ‘best in class’ preclinical drug discovery
capabilities."
Gerald Evans, BioLeap Chief Business Officer
added, "
We are delighted to have the opportunity to offer our
partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the
innovation capabilities of Jubilant Biosys in pharmaceutical discovery and
preclinical development with BioLeap’s leading edge computational
fragment-based design capabilities, to deliver high quality, cost-effective
pre-clinical drug discovery services."
BioLeap’s platform
technology is completely
“in-silico”, and it quickly predicts
binding information providing drug designers new insights to efficiently create
novel molecules and/or improve existing molecules without the limitations of
library screening, thereby reducing the time and cost of traditional screening
methods.
Many current
screening programs have hit barriers with regards to finding small molecule
candidates for viable validated targets because of limitations in chemical
diversity. BioLeap’s technology provides a viable solution to this current
paradigm. The combined strengths of JBL/BioLeap partnership would be most
attractive to companies engaged in rational drug design in therapeutic areas
where Structural Biology plays a key role, which includes but is not limited to
any of the top twenty pharmaceutical companies working on anti-infectives, oncology, CNS and other therapeutic areas.
About Jubilant Biosys
Jubilant Biosys Ltd.
(www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., which
provides integrated drug discovery and development solutions to the global
pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys
Center in Bangalore integrates the capabilities of over 300 scientists
specializing in multiple disciplines including biology, chemistry, structural
biology, pharmacology, molecular modeling, crystallography and information technology
to support collaborations with global pharma companies in USA, Europe and Japan.
About Jubilant Organosys
Jubilant Organosys
Ltd. is an integrated pharmaceutical industry player, one of the largest custom
research and manufacturing services (CRAMS) and drug discovery and development
services companies out of India. The company has a presence across the
pharmaceutical value chain for products and services such as proprietary
products ,exclusive synthesis, active pharmaceutical ingredients, contract
manufacturing of sterile injectables (liquids and lyophilized) products,
non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug
discovery services, medicinal chemistry services, clinical research services
,generic dosage forms and Health Care. Jubilant Organosys has geographically
diversified manufacturing facilities at ten locations worldwide. Together,
these help Jubilant cater to 150 customers across more than 50 countries around
the world.
About BioLeapBioLeap is a leader
in computational fragment-based drug design.
The company’s proprietary design technology and process successfully
addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable
leads for important biological targets.
BioLeap is using its capabilities to advance its internal programs and
has also entered into numerous drug design collaborations with pharmaceutical
partners. Further information
about Jubilant Organosys is available at
www.jubl.com about BioLeap at
www.bioleap.com.
---ENDS---
For further information :
|
|
|
|
|
|
|
|
|
|
|
|
|
Jubilant Organosys Limited |
Jubilant Organosys Limited |
|
1-A, Sector 16-A, Institutional Area |
1-A, Sector 16-A, Institutional Area |
|
Noida - 201301 (UP) |
Noida - 201301 (UP) |
|
Ph: +91-120-4361062 |
Ph: +91-120-4361114 |
|
Mobile - +91-9810631779 |
|
|
Email:
seema_ahuja@jubl.com |
|
Disclaimer:
Statements in this
document relating to future status, events, or
circumstances, including but not limited to statements about
plans and objectives, the progress and results of research
and development, potential product characteristics and uses,
product sales potential and target dates for product launch
are forward-looking statements based on estimates and the
anticipated effects of future events on current and
developing circumstances. Such statements are subject to
numerous risks and uncertainties and are not necessarily
predictive of future results. Actual results may differ
materially from those anticipated in the forward-looking
statements. Jubilant Organosys may, from time to time, make
additional written and oral forward looking statements,
including statements contained in the company's filings with
the regulatory bodies and our reports to shareholders. The
company assumes no obligation to update forward-looking
statements to reflect actual results, changed assumptions or
other factors.
|
